Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06541132

Positive Association of US-FLI With the Severity of CAD

Positive Association Between Ultrasonographic Fatty Liver Indicator and the Severity of Coronary Artery Disease

Status
Recruiting
Phase
Study type
Observational
Enrollment
190 (estimated)
Sponsor
Chongqing Medical University · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Accepted

Summary

As a multisystem disease, metabolic dysfunction-associated fatty liver disease (MAFLD) is closely linked to the onset and progression of coronary heart disease (CHD). Ultrasonographic fatty liver indicator (US-FLI) is a semi-quantitative tool for evaluating the degree of hepatic steatosis. Our study aims to explore the relationship between US-FLI based on MAFLD and the severity of CHD.

Detailed description

204 patients who had invasive coronary angiography performed between July 2022 and December 2023 at the cardiology department of the Second Affiliated Hospital of Chongqing Medical University were included in this study. Collect clinical information and abdominal ultrasound images from each patient. Hepatic steatosis which quantified by US-FLI was evaluated by the echo contrast between liver and kidney, posterior attenuation of ultrasound beam, areas of focal sparing, display of hepatic vessels, gallbladder wall and diaphragm. Fatty liver was diagnosed when US-FLI≥2. The severity of CHD was evaluated using the SYNTAX score (SS), and a total of 100 CHD patients were ultimately diagnosed. CHD patients were further divided into the low-risk group (SS ≤ 22) (54 cases) and the medium-high-risk group (SS≥23) (46 cases). Multivariate logistic regression model was used to assess the relationship between US-FLI and SS in patients with MAFLD. The receiver operating characteristic curve was used to determine the accuracy, sensitivity and specificity of US-FLI in predicting SS.

Conditions

Interventions

TypeNameDescription
OTHERObservational study without human interventionObservational study without human intervention

Timeline

Start date
2022-07-01
Primary completion
2025-04-28
Completion
2025-04-28
First posted
2024-08-07
Last updated
2024-08-21

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06541132. Inclusion in this directory is not an endorsement.